144 related articles for article (PubMed ID: 38101998)
21. T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project.
Patel SH; Poisson LM; Brat DJ; Zhou Y; Cooper L; Snuderl M; Thomas C; Franceschi AM; Griffith B; Flanders AE; Golfinos JG; Chi AS; Jain R
Clin Cancer Res; 2017 Oct; 23(20):6078-6085. PubMed ID: 28751449
[No Abstract] [Full Text] [Related]
22. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
[TBL] [Abstract][Full Text] [Related]
23. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
[TBL] [Abstract][Full Text] [Related]
24. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
[TBL] [Abstract][Full Text] [Related]
26. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
27. T
Kinoshita M; Uchikoshi M; Sakai M; Kanemura Y; Kishima H; Nakanishi K
Magn Reson Med Sci; 2021 Mar; 20(1):119-123. PubMed ID: 32101817
[TBL] [Abstract][Full Text] [Related]
28. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
[TBL] [Abstract][Full Text] [Related]
29. Glioma grading using multiparametric MRI: head-to-head comparison among dynamic susceptibility contrast, dynamic contrast-enhancement, diffusion-weighted images, and MR spectroscopy.
Seo M; Choi Y; Soo Lee Y; Ahn KJ; Kim BS; Park JS; Jeon SS
Eur J Radiol; 2023 Aug; 165():110888. PubMed ID: 37257338
[TBL] [Abstract][Full Text] [Related]
30. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
[TBL] [Abstract][Full Text] [Related]
31. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
[TBL] [Abstract][Full Text] [Related]
32. T2-Fluid-Attenuated Inversion Recovery (FLAIR) Mismatch as a Novel Specific MRI Marker for Adult Low-Grade Glioma (LGG): A Case Report.
Slaghour RM; Almarshedi RA; Alzahrani AM; Albadr F
Cureus; 2022 Sep; 14(9):e29457. PubMed ID: 36299937
[TBL] [Abstract][Full Text] [Related]
33. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.
Mancini L; Casagranda S; Gautier G; Peter P; Lopez B; Thorne L; McEvoy A; Miserocchi A; Samandouras G; Kitchen N; Brandner S; De Vita E; Torrealdea F; Rega M; Schmitt B; Liebig P; Sanverdi E; Golay X; Bisdas S
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2377-2391. PubMed ID: 35029738
[TBL] [Abstract][Full Text] [Related]
34. Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign.
Kihira S; Derakhshani A; Leung M; Mahmoudi K; Bauer A; Zhang H; Polson J; Arnold C; Tsankova NM; Hormigo A; Salehi B; Pham N; Ellingson BM; Cloughesy TF; Nael K
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831380
[TBL] [Abstract][Full Text] [Related]
35. Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas.
Mohammed S; Ravikumar V; Warner E; Patel SH; Bakas S; Rao A; Jain R
AJNR Am J Neuroradiol; 2022 Jan; 43(1):33-39. PubMed ID: 34764084
[TBL] [Abstract][Full Text] [Related]
36. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract][Full Text] [Related]
37. Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system.
Nam YK; Park JE; Park SY; Lee M; Kim M; Nam SJ; Kim HS
Eur Radiol; 2021 Oct; 31(10):7374-7385. PubMed ID: 34374800
[TBL] [Abstract][Full Text] [Related]
38. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
[TBL] [Abstract][Full Text] [Related]
39. Patterns of T2-FLAIR discordance across a cohort of adult-type diffuse gliomas and deviations from the classic T2-FLAIR mismatch sign.
Malik P; Soliman R; Chen YA; Munoz DG; Das S; Bharatha A; Mathur S
Neuroradiology; 2024 Apr; 66(4):521-530. PubMed ID: 38347151
[TBL] [Abstract][Full Text] [Related]
40. T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
Throckmorton P; Graber JJ
Neurology; 2020 Sep; 95(11):e1582-e1589. PubMed ID: 32690782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
